BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
CAB Platform Promise | BioAtla's innovative conditionally active biologics aim to revolutionize cancer treatment, enhancing potency while reducing side effects |
Financial Fortitude | Strong liquidity with $32M cash, extended runway to 2026, and strategic cost-cutting measures position BioAtla for continued clinical advancement |
Pipeline Progress | Explore BioAtla's promising candidates, including BA3182 and Mec-V, showing encouraging anti-tumor activity in ongoing clinical trials |
Market Outlook | Analysts set price targets ranging from $1 to $5, reflecting cautious optimism amid BioAtla's pivotal year of clinical developments and partnership pursuits |
Metrics to compare | BCAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCABPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.4x | −1.2x | −0.5x | |
PEG Ratio | −0.01 | −0.05 | 0.00 | |
Price/Book | −1.6x | 1.7x | 2.6x | |
Price / LTM Sales | 2.4x | 8.4x | 3.3x | |
Upside (Analyst Target) | - | 286.0% | 38.9% | |
Fair Value Upside | Unlock | 31.1% | 5.4% | Unlock |